EMA Authorised: Myqorzo (aficamten) — Cytokinetics (Ireland) Limited

View source ↗

Summary

The European Medicines Agency authorised Myqorzo (aficamten) for the treatment of hypertrophic cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• MYQORZO (aficamten)

Snippet

Status: Authorised. Therapeutic area: Cardiomyopathy, Hypertrophic. MAH: Cytokinetics (Ireland) Limited. Decision date: 15/04/2026